Strs Ohio Makes New Investment in Voyager Therapeutics, Inc. $VYGR

Key Points

• Strs Ohio has acquired a new position in Voyager Therapeutics, buying 75,800 shares valued at approximately $256,000, representing about 0.14% of the company.
• Voyager Therapeutics' stock price is currently at $4.25, with a market capitalization of $235.74 million and a twelve-month high of $8.27.
• Despite recent investments, Voyager reported negative earnings of ($0.57) EPS for the last quarter, missing estimates and prompting varied analyst forecasts with a consensus price target of $13.25.

Strs Ohio purchased a new position in Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 75,800 shares of the company's stock, valued at approximately $256,000. Strs Ohio owned approximately 0.14% of Voyager Therapeutics at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of VYGR. CWM LLC grew its stake in Voyager Therapeutics by 856.3% during the 1st quarter. CWM LLC now owns 10,471 shares of the company's stock valued at $35,000 after acquiring an additional 9,376 shares in the last quarter. Privium Fund Management B.V. acquired a new position in shares of Voyager Therapeutics in the first quarter valued at $73,000. Virtus Advisers LLC acquired a new position in shares of Voyager Therapeutics in the first quarter valued at $83,000. Invesco Ltd. raised its stake in shares of Voyager Therapeutics by 100.8% in the first quarter. Invesco Ltd. now owns 48,540 shares of the company's stock valued at $164,000 after purchasing an additional 24,368 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its stake in Voyager Therapeutics by 53.8% during the first quarter. Allspring Global Investments Holdings LLC now owns 60,462 shares of the company's stock worth $204,000 after acquiring an additional 21,149 shares in the last quarter. Hedge funds and other institutional investors own 48.03% of the company's stock.

Voyager Therapeutics Stock Up 3.7%

NASDAQ:VYGR opened at $4.25 on Thursday. The firm has a market capitalization of $235.74 million, a price-to-earnings ratio of -2.30 and a beta of 0.90. Voyager Therapeutics, Inc. has a twelve month low of $2.64 and a twelve month high of $8.27. The stock's 50 day moving average price is $3.62 and its two-hundred day moving average price is $3.43.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.09). Voyager Therapeutics had a negative return on equity of 37.65% and a negative net margin of 253.49%.The business had revenue of $5.20 million for the quarter, compared to the consensus estimate of $9.50 million. As a group, analysts anticipate that Voyager Therapeutics, Inc. will post -0.91 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Wedbush dropped their price objective on Voyager Therapeutics from $9.00 to $8.00 and set an "outperform" rating for the company in a research note on Thursday, August 7th. HC Wainwright restated a "buy" rating and set a $30.00 target price on shares of Voyager Therapeutics in a report on Monday, September 15th. One analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $13.25.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.

Want to see what other hedge funds are holding VYGR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.